CDK4 and familial pancreatic carcinoma: Our findings are in accordance with the synergistic antitumoral effects of MEKi and CDK4/6i shown in various other tumor cell models, including neuroblastoma [23], neuroendocrine prostate carcinoma [43], melanoma [28,44,45], colorectal cancer [24,25,46], pancreatic cancer [47] and NSCLC models [26].